ISRG · News · 20260817N
Competition and New Entrants
INTUITIVE SURGICAL INC · 2026-08-17 · Importance 47 · Surprise 60 · In source text
Johnson & Johnson received FDA clearance for its Ottava robotic system, introducing a significant new competitor to Intuitive Surgical in soft-tissue surgery. The report identifies U.S. da Vinci procedure growth as a key determinant of Intuitive’s future performance. Investors are also expected to monitor how quickly Ottava gains market share after entering the market. Intuitive’s reported 19% revenue increase indicates continued demand despite the competitive threat.
Key facts
- The decline in Intuitive's stock was attributed primarily to the FDA clearance of Johnson & Johnson’s Ottava robot, introducing a significant rival in soft-tissue surgery. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | The decline in Intuitive's stock was attributed primarily to the FDA clearance of Johnson & Johnson’s Ottava robot, introducing a… |